|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
361,116 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
O'connor Daniel |
Chief Executive Officer |
|
2016-12-30 |
4 |
A |
$7.16 |
$5,671 |
D/D |
792 |
295,814 |
|
- |
|
Mayes Gregory T. |
Director |
|
2016-12-30 |
4 |
D |
$7.16 |
$852 |
D/D |
(119) |
103,841 |
|
- |
|
Mayes Gregory T. |
Director |
|
2016-12-30 |
4 |
A |
$7.16 |
$3,279 |
D/D |
458 |
103,960 |
|
- |
|
Mckearn Thomas J |
Director |
|
2016-12-20 |
4 |
S |
$8.08 |
$99,513 |
D/D |
(12,316) |
69,804 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-11-30 |
4 |
D |
$8.31 |
$457 |
D/D |
(55) |
81,963 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-11-30 |
4 |
A |
$8.31 |
$2,036 |
D/D |
245 |
82,018 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-11-30 |
4 |
D |
$8.31 |
$407 |
D/D |
(49) |
120,969 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-11-30 |
4 |
A |
$8.31 |
$2,277 |
D/D |
274 |
121,018 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-11-30 |
4 |
D |
$8.31 |
$482 |
D/D |
(58) |
103,502 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-11-30 |
4 |
A |
$8.31 |
$2,186 |
D/D |
263 |
103,560 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-11-30 |
4 |
D |
$8.31 |
$740 |
D/D |
(89) |
295,022 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-11-30 |
4 |
A |
$8.31 |
$3,781 |
D/D |
455 |
295,111 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-11-02 |
4 |
S |
$8.32 |
$23,271 |
D/D |
(2,797) |
120,744 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-11-02 |
4 |
S |
$8.32 |
$68,557 |
D/D |
(8,240) |
294,656 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-10-31 |
4 |
D |
$8.09 |
$485 |
D/D |
(60) |
103,297 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-10-31 |
4 |
A |
$8.09 |
$2,184 |
D/D |
270 |
103,357 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-10-31 |
4 |
D |
$8.09 |
$453 |
D/D |
(56) |
81,773 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-10-31 |
4 |
A |
$8.09 |
$2,039 |
D/D |
252 |
81,829 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-10-31 |
4 |
D |
$8.09 |
$955 |
D/D |
(118) |
123,541 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-10-31 |
4 |
A |
$8.09 |
$2,273 |
D/D |
281 |
123,659 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-10-31 |
4 |
D |
$8.09 |
$1,869 |
D/D |
(231) |
302,896 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-10-31 |
4 |
A |
$8.09 |
$3,778 |
D/D |
467 |
303,127 |
|
- |
|
Mayes Gregory T. |
Chief Business Officer |
|
2016-10-25 |
4 |
S |
$8.23 |
$157,703 |
D/D |
(19,162) |
103,087 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-09-30 |
4 |
D |
$10.69 |
$342 |
D/D |
(32) |
123,378 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-09-30 |
4 |
A |
$10.69 |
$2,277 |
D/D |
213 |
123,410 |
|
- |
|
586 Records found
|
|
Page 5 of 24 |
|
|